Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Bio-Techne (TECH) to $58 from $51 and keeps a Neutral rating on the shares. The firm updated its modelafter previewing its upcoming Q4 results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher
- Bio-Techne resumed with an Overweight at Stephens
- Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection
- Bio-Techne initiated with a Buy at TD Cowen
- Bio-Techne: Undervalued Stock with Strong Growth Potential and Margin Expansion Opportunities